We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.20 | 3.03% | 40.76 | 40.59 | 40.80 | 40.80 | 40.12 | 40.15 | 2,775,124 | 22:20:00 |
From Jul 2023 to Jul 2024
By Cecilia Butini
Roche said Wednesday that the U.S. Food and Drug Administration has accepted its application for monoclonal antibody crovalimab for the treatment of rare blood condition paroxysmal nocturnal hemoglobinuria.
The government agency has accepted Roche's Biologics License Application, which is required to introduce a biologic product to the market, based on results from a Phase 3 study. It hasn't yet given the drug full approval, and the drug is still being investigated in a series of studies, Roche said.
If approved, however, crovalimab would be the first monthly subcutaneous treatment for paroxysmal nocturnal hemoglobinuria and would allow patients to self-administer the treatment outside of supervised health-care settings, according to the company.
Paroxysmal nocturnal hemoglobinuria causes symptoms like anemia, fatigue and blood clots, and affects about 20,000 worldwide, said Roche.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
September 06, 2023 01:37 ET (05:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
